Tirzepatide

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Developed by Eli Lilly, it is the first dual incretin receptor agonist approved for clinical use and represents a significant advance in the treatment of type 2 diabetes mellitus (as Mounjaro) and chronic weight management (as Zepbound).

Overview

Tirzepatide uniquely engages both the GIP and GLP-1 receptors, combining the metabolic benefits of two incretin pathways in a single molecule. Its extended half-life of approximately five days is achieved through a C20 fatty diacid moiety linked to lysine at position 20, which promotes albumin binding and slows renal clearance, enabling convenient once-weekly subcutaneous dosing. Tirzepatide is marketed as Mounjaro for type 2 diabetes mellitus and Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone secreted by K-cells of the upper small intestine in response to nutrient intake. It potentiates glucose-dependent insulin secretion and plays roles in lipid metabolism and adipose tissue function. By combining GIP receptor agonism with GLP-1 receptor agonism, tirzepatide achieves metabolic effects that exceed those of selective GLP-1 receptor agonists alone.

Mechanism of Action

Tirzepatide activates both incretin receptor pathways through coordinated physiological mechanisms:

GIP Receptor Agonism: Tirzepatide binds GIP receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion. GIP receptor activation also influences lipid metabolism in adipose tissue, potentially improving fat storage efficiency and reducing ectopic lipid deposition.

GLP-1 Receptor Agonism: Like selective GLP-1 receptor agonists, tirzepatide stimulates glucose-dependent insulin release, suppresses glucagon secretion from alpha cells, slows gastric emptying, and promotes satiety through central nervous system GLP-1 receptor activation.

Dual Incretin Synergy: The combination of GIP and GLP-1 receptor activation produces synergistic effects on glycemic control and body weight reduction that surpass those achieved by GLP-1 receptor agonism alone. The GIP component may also mitigate some GI tolerability issues associated with GLP-1 receptor agonists.

Central Appetite Regulation: Tirzepatide acts on hypothalamic and brainstem receptors to reduce appetite and caloric intake, contributing to the substantial weight loss observed in clinical trials.

Beta Cell Function: Dual incretin receptor activation improves beta cell function and insulin sensitivity, addressing core pathophysiological defects in type 2 diabetes.

Reconstitution Calculator

Reconstitution Calculator

Calculate your peptide dosing

Draw Volume
0.100mL
Syringe Units
10units
Concentration
2,500mcg/mL
Doses / Vial
20doses
Vial Total
5mg
Waste / Vial
0mcg
Syringe Cap.
100units · 1mL
How to reconstitute
Gather & prepare
1/6Gather & prepare

Set up a clean workspace with all supplies ready.

1.Wash hands thoroughly, put on disposable gloves
2.Your 5mg peptide vial (lyophilized powder)
3.Bacteriostatic water (you'll need 2mL)
4.A 3–5mL syringe with 21–25 gauge needle for reconstitution
5.Alcohol swabs (70% isopropyl)
Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials. Sterile water is only safe for single-use.
Supply Planner

7x / week for weeks

·
40%
2vials
28 doses20 days/vial12 leftover
Cost Breakdown
Vial price
$0.00per dose
$0.00 /week$0 /month
Store 2-8°C30 day shelf lifeSwirl gentlyFor research purposes only

Research

Obesity and Weight Management (SURMOUNT Program)

The SURMOUNT-1 trial evaluated tirzepatide in adults with obesity or overweight without type 2 diabetes. Participants receiving the highest dose (15 mg) achieved a mean body weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo. More than one-third of participants in the 15 mg group lost at least 25% of their body weight, establishing tirzepatide as the most effective pharmacotherapy for obesity studied in randomized controlled trials at the time of publication. Jastreboff AM et al. (2022) — N. Engl. J. Med.

Liver Fat Reduction (NASH/MAFLD)

Tirzepatide has demonstrated significant reductions in liver fat content in patients with type 2 diabetes. In a substudy of the SURPASS-3 trial, tirzepatide reduced liver fat by up to 8.09 percentage points from baseline compared to 3.38 percentage points with insulin degludec, as measured by MRI-proton density fat fraction. These findings support the investigation of tirzepatide as a potential treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). Gastaldelli A et al. (2022) — Lancet Diabetes Endocrinol.

Ongoing & Future Research

Several large-scale trials are actively investigating tirzepatide in new indications and long-term outcomes:

  • SURMOUNT-MMO (NCT05260021): A landmark cardiovascular outcomes trial evaluating whether tirzepatide reduces major adverse cardiovascular events (MACE: cardiovascular death, myocardial infarction, or stroke) in adults with obesity but without diabetes. This event-driven trial enrolled ~15,000 participants and is expected to provide definitive evidence on tirzepatide's cardiovascular benefit in obesity. Estimated completion: 2027.

  • SURPASS-CVOT (NCT04255433): A dedicated cardiovascular outcomes trial in patients with type 2 diabetes and established atherosclerotic cardiovascular disease, comparing tirzepatide versus dulaglutide. Results published in 2024 showed non-inferiority for MACE with signals of superiority. Sattar N et al. (2024) — DOI: 10.1016/S0140-6736(24)02107-802107-8)

  • SURMOUNT-OSA (NCT05024032): A Phase 3 trial examining tirzepatide's effect on obstructive sleep apnea (OSA) severity. Tirzepatide reduced the apnea-hypopnea index (AHI) by approximately 50% in patients with moderate-to-severe OSA, with some participants achieving AHI reductions sufficient to discontinue CPAP therapy. Malhotra A et al. (2024) — N. Engl. J. Med. 391, 1288-1298. PMID: 38912654

  • Heart Failure with Preserved Ejection Fraction (HFpEF) (NCT04847557): SUMMIT trial evaluating tirzepatide in patients with obesity-related HFpEF. Initial results demonstrated significant improvements in a composite endpoint of heart failure symptoms, exercise capacity (6-minute walk test), and Kansas City Cardiomyopathy Questionnaire scores. Packer M et al. (2025) — N. Engl. J. Med. 392, 427-437. PMID: 39536298

  • MASH/NASH (NCT04166773): SYNERGY-NASH trial examining tirzepatide's effect on metabolic dysfunction-associated steatohepatitis, with histological endpoints including NASH resolution and fibrosis improvement. Phase 2 data demonstrated MASH resolution in 44-62% of participants across doses.

  • Chronic Kidney Disease (NCT05536804): SURMOUNT-5 is evaluating tirzepatide's renal outcomes in patients with obesity and CKD, building on observations of reduced albuminuria in earlier SURPASS trials.

Cardiovascular Outcomes

The SURPASS-CVOT trial investigated cardiovascular outcomes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Results demonstrated that tirzepatide was non-inferior to the active comparator for major adverse cardiovascular events (MACE), with signals suggesting potential cardiovascular benefit. Reductions in blood pressure, lipid parameters, and inflammatory markers observed across the SURPASS program support a favorable cardiometabolic profile. Sattar N et al. (2024) — Cardiovascular outcomes with tirzepatide.02107-8)

Type 2 Diabetes (SURPASS Program)

The SURPASS clinical trial program established tirzepatide as a highly effective treatment for type 2 diabetes. In the SURPASS-2 trial, tirzepatide demonstrated superior HbA1c reduction compared to semaglutide 1 mg, with tirzepatide 15 mg achieving a mean HbA1c reduction of 2.46% versus 1.86% with semaglutide. Tirzepatide also produced significantly greater body weight reduction across all doses tested. Frias JP et al. (2021) — N. Engl. J. Med.

Comparison to Related Compounds

ParameterTirzepatide (15 mg)Semaglutide 2.4 mg (Wegovy)Liraglutide 3.0 mg (Saxenda)Retatrutide (12 mg)
Receptor targetsGIP + GLP-1GLP-1 onlyGLP-1 onlyGIP + GLP-1 + Glucagon
Dosing frequencyOnce weeklyOnce weeklyOnce dailyOnce weekly
HbA1c reduction (T2DM)−2.46%−1.86% (1 mg dose)*−1.1 to −1.5%−2.16% (Phase 2)
Weight loss (obesity, non-T2DM)−22.5% (72 wk)−15.8% (68 wk)−8.0% (56 wk)−24.2% (48 wk, Phase 2)
≥20% weight loss achieved36% (15 mg, SURMOUNT-1)15% (STEP-1)~4%26% (12 mg, Phase 2)
Half-life~5 days~7 days~13 hours~6 days

*SURPASS-2 compared tirzepatide against semaglutide 1 mg (Ozempic dose), not the 2.4 mg obesity dose (Wegovy).

Tirzepatide vs. Semaglutide (SURPASS-2 Head-to-Head): In the only direct head-to-head trial of these agents, tirzepatide at all three doses (5, 10, 15 mg) was non-inferior to semaglutide 1 mg for HbA1c reduction, and the 10 mg and 15 mg doses were statistically superior. The estimated treatment difference for tirzepatide 15 mg versus semaglutide 1 mg was −0.60 percentage points for HbA1c and −5.5 kg for body weight. Gastrointestinal adverse events occurred at similar rates across both drugs. A key caveat is that semaglutide was studied at its diabetes dose (1 mg), not the higher 2.4 mg weight management dose. Frias JP et al. (2021) — PMID: 34170647

Tirzepatide vs. Liraglutide: No direct head-to-head trial exists. Cross-trial comparisons suggest tirzepatide produces approximately 2-3 times the weight loss observed with liraglutide 3.0 mg (~22% vs ~8%) and substantially greater HbA1c reductions (~2.4% vs ~1.3%). Tirzepatide's once-weekly dosing offers improved convenience over liraglutide's daily injections. The dual GIP/GLP-1 mechanism may also contribute to better gastrointestinal tolerability, as GIP receptor activation appears to counterbalance some GLP-1-mediated nausea. Frias JP et al. (2021) — PMID: 34170647; Pi-Sunyer X et al. (2015) — PMID: 26132939

Tirzepatide vs. Retatrutide: Retatrutide (LY3437943) is a triple agonist (GIP/GLP-1/glucagon receptor) also developed by Eli Lilly. Phase 2 data showed retatrutide 12 mg achieved −24.2% weight loss at 48 weeks, with some participants losing >30% body weight. The addition of glucagon receptor agonism may enhance energy expenditure and hepatic lipid clearance beyond what dual agonism achieves. Direct Phase 3 comparisons are anticipated. Jastreboff AM et al. (2023) — N. Engl. J. Med. 389, 514-526. PMID: 37385337

Safety Profile

Common adverse effects include gastrointestinal symptoms such as nausea (12-18%), diarrhea, vomiting, and decreased appetite, which are typically mild to moderate in severity and tend to diminish with continued treatment and gradual dose escalation. Injection site reactions occur infrequently. Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent studies; the relevance to humans has not been determined. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Additional warnings include pancreatitis, gallbladder disease, and hypoglycemia when used in combination with insulin or sulfonylureas. Dose-dependent increases in heart rate (2-4 bpm) have been observed, consistent with the GLP-1 receptor agonist class.

Pharmacokinetic Profile

Tirzepatide — Pharmacokinetic Curve

Subcutaneous injection (once weekly)
0%25%50%75%100%0m5d10d15d20d25dTimeConcentration (% peak)T_max 30hT_1/2 5d
Half-life: 5dT_max: 24hDuration shown: 25d

Quick Start

Typical Dose
2.5mg starting, titrate up to 5-15mg weekly
Frequency
Once weekly (same day each week)
Route
Subcutaneous injection (once weekly)
Cycle Length
Ongoing therapy as prescribed
Storage
Pen: 2-8°C before first use, room temp up to 21 days after. Compounded: 2-8°C

Molecular Structure

2D Structure
Tirzepatide molecular structure
Molecular Properties
Formula
C225H348N48O68
Weight
4,813.55 Da Da
Length
39 amino acids
CAS
2023788-19-2
PubChem CID
156588324
Exact Mass
4812.5316 Da
LogP
-6.8
TPSA
1790 Ų
H-Bond Donors
58
H-Bond Acceptors
70
Rotatable Bonds
163
Complexity
11700
Identifiers (SMILES, InChI)
InChI
InChI=1S/C225H348N48O68/c1-23-126(10)183(214(327)242-131(15)190(303)244-148(80-84-168(228)283)196(309)245-145(64-50-52-88-226)195(308)240-130(14)191(304)248-154(105-135-58-42-40-43-59-135)205(318)263-182(125(8)9)212(325)247-149(81-85-169(229)284)197(310)251-156(108-139-111-234-144-63-49-48-62-142(139)144)201(314)249-151(102-123(4)5)204(317)265-184(127(11)24-2)213(326)241-129(13)189(302)236-112-173(288)235-115-177(292)270-92-54-66-164(270)210(323)258-161(118-276)208(321)256-160(117-275)194(307)238-113-174(289)239-132(16)218(331)272-94-56-68-166(272)220(333)273-95-57-69-167(273)219(332)271-93-55-67-165(271)211(324)255-159(116-274)188(230)301)264-198(311)146(65-51-53-89-231-170(285)70-46-38-36-34-32-30-28-26-27-29-31-33-35-37-39-47-71-172(287)243-150(221(334)335)82-86-171(286)232-90-96-338-98-100-340-121-176(291)233-91-97-339-99-101-341-122-181(299)300)246-202(315)157(109-179(295)296)252-199(312)152(103-124(6)7)261-223(337)225(21,22)269-217(330)185(128(12)25-3)266-209(322)163(120-278)257-200(313)153(107-138-74-78-141(282)79-75-138)250-203(316)158(110-180(297)298)253-207(320)162(119-277)259-216(329)187(134(18)280)267-206(319)155(106-136-60-44-41-45-61-136)254-215(328)186(133(17)279)262-175(290)114-237-193(306)147(83-87-178(293)294)260-222(336)224(19,20)268-192(305)143(227)104-137-72-76-140(281)77-73-137/h40-45,48-49,58-63,72-79,111,123-134,143,145-167,182-187,234,274-282H,23-39,46-47,50-57,64-71,80-110,112-122,226-227H2,1-22H3,(H2,228,283)(H2,229,284)(H2,230,301)(H,231,285)(H,232,286)(H,233,291)(H,235,288)(H,236,302)(H,237,306)(H,238,307)(H,239,289)(H,240,308)(H,241,326)(H,242,327)(H,243,287)(H,244,303)(H,245,309)(H,246,315)(H,247,325)(H,248,304)(H,249,314)(H,250,316)(H,251,310)(H,252,312)(H,253,320)(H,254,328)(H,255,324)(H,256,321)(H,257,313)(H,258,323)(H,259,329)(H,260,336)(H,261,337)(H,262,290)(H,263,318)(H,264,311)(H,265,317)(H,266,322)(H,267,319)(H,268,305)(H,269,330)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,334,335)/t126-,127-,128-,129-,130-,131-,132-,133+,134+,143-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,182-,183-,184-,185-,186-,187-/m0/s1
InChIKeyAAPYRSPHYSKGIS-MCNPHUAVSA-N

Research Indications

Weight Loss

Strong Evidence
Severe Obesity Management

Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals, superior to existing weight loss medications.

Strong Evidence
Metabolic Syndrome Reversal

Improvements in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers.

Good Evidence
Body Composition Optimization

Preferentially reduces visceral adipose tissue while preserving lean muscle mass with resistance training.

Diabetes

Strong Evidence
Type 2 Diabetes Management

Superior HbA1c reduction of 1.5-2.4% in clinical trials.

Good Evidence
Insulin Resistance Improvement

Improves insulin sensitivity across diverse populations.

Good Evidence
Beta Cell Preservation

May help preserve and restore pancreatic beta cell function.

Cardiovascular

Good Evidence
MACE Reduction

26% reduction in major adverse cardiovascular events demonstrated in SURPASS-CVOT trial.

Good Evidence
Blood Pressure Reduction

Systolic and diastolic blood pressure reductions of 8-12 mmHg.

Moderate Evidence
Lipid Profile Improvement

Triglyceride improvements of 20-30%, HDL enhancement, and apolipoprotein B reduction.

Research Protocols

subcutaneous Injection

Dual GIP/GLP-1 receptor agonist administered once weekly. Slow dose escalation to minimize GI side effects.

GoalDoseFrequency
Initiation2.5 mgOnce weekly
Escalation 15.0 mgOnce weekly
Escalation 27.5 mgOnce weekly
Escalation 310 mgOnce weekly
Maintenance5-15 mgOnce weekly
Reconstitution Guide (5mg vial + 2mL BAC water)
  1. Wipe vial tops with alcohol swab
  2. Draw 2.0 mL bacteriostatic water into syringe
  3. Inject slowly down the inside wall of the peptide vial
  4. Gently swirl to dissolve — never shake
  5. Resulting concentration: 2.5 mg/mL
  6. For 2.5 mg dose: draw 100 units (1.00 mL)
  7. For 5.0 mg dose: draw 200 units (2.00 mL) — requires 2 full syringes
  8. Store reconstituted vial refrigerated at 2-8°C

Interactions

Peptide Interactions

GLP-1compatible

Dose-dependent increases in heart rate (2-4 bpm) have been observed, consistent with the GLP-1 receptor agonist class.

What to Expect

What to Expect

Day 1-3

Appetite reduction begins

Week 1-2

Improved blood sugar control (diabetics), mild nausea common

Week 2-4

Initial weight loss begins; GI side effects typically improve

Ongoing

1-3 lbs weight loss per week during active phase

Week 16-24

Peak weight loss effects observed

Safety Profile

Common Side Effects

  • Nausea (mild to moderate, first 2-4 weeks)
  • Appetite reduction
  • Possible fatigue during adaptation
  • Diarrhea or constipation
  • Reduced food cravings

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • Pregnancy or breastfeeding
  • History of pancreatitis

Discontinue If

  • Severe/persistent abdominal pain (pancreatitis risk)
  • Neck lumps, hoarseness, difficulty swallowing (thyroid concerns)
  • Severe nausea/vomiting preventing adequate nutrition
  • Severe hypoglycemic signs (confusion, sweating, rapid heartbeat)
  • Kidney problems (decreased urination, swelling)
  • Severe allergic reactions (rash, breathing difficulty)
  • Suicidal thoughts or severe depression
  • Gallbladder problems (severe upper right pain)
  • Dehydration from persistent vomiting

Quality Indicators

What to look for

  • White to off-white lyophilized powder without clumping
  • Clear, colorless reconstituted solution
  • Intact vial seal with visible mg dosage labeling and batch numbers
  • Proper storage maintenance at 2-8°C, protected from light

Caution

  • Compounded versions without proper quality control

Red flags

  • Powder clumping, discoloration, or yellow/brown appearance
  • Persistent cloudiness after reconstitution
  • Unusual crystallization patterns

Frequently Asked Questions

References (8)

  1. [1]
    SURMOUNT-1 Phase 3 Trial (2022)
  2. [2]
    SURPASS Clinical Program (2021)
  3. [3]
    SURMOUNT-2 T2DM Trial (2023)
  4. [4]
    SURPASS-CVOT Cardiovascular Outcomes (2023)
  5. [8]
  6. [5]
  7. [6]
    Jastreboff, A. M. et al Tirzepatide Once Weekly for the Treatment of Obesity N. Engl. J. Med. (2022)
  8. [7]
    Gastaldelli, A. et al Effect of tirzepatide versus insulin degludec on liver fat content Lancet Diabetes Endocrinol. (2022)
Updated 2026-03-08Sources: jabronistore-wiki, peptide-wiki-mdx, pep-pedia, pubchem, peptide-wiki-mdx-v2

On this page